WO2004043383A8 - A new target for angiogenesis and anti-angiogenesis therapy - Google Patents
A new target for angiogenesis and anti-angiogenesis therapyInfo
- Publication number
- WO2004043383A8 WO2004043383A8 PCT/US2003/035633 US0335633W WO2004043383A8 WO 2004043383 A8 WO2004043383 A8 WO 2004043383A8 US 0335633 W US0335633 W US 0335633W WO 2004043383 A8 WO2004043383 A8 WO 2004043383A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- angiogenesis
- new target
- therapy
- useful
- compositions
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/515—Angiogenesic factors; Angiogenin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/529,116 US7462593B2 (en) | 2002-11-07 | 2003-11-07 | Compositions and methods for promoting angiogenesis |
JP2004551922A JP5068428B2 (en) | 2002-11-07 | 2003-11-07 | Targets for angiogenesis and anti-angiogenic therapy |
AU2003295422A AU2003295422B2 (en) | 2002-11-07 | 2003-11-07 | A new target for angiogenesis and anti-angiogenesis therapy |
CA2504953A CA2504953C (en) | 2002-11-07 | 2003-11-07 | A new target for angiogenesis and anti-angiogenesis therapy |
EP03786608A EP1575511A4 (en) | 2002-11-07 | 2003-11-07 | A new target for angiogenesis and anti-angiogenesis therapy |
US12/240,656 US7862815B2 (en) | 2002-11-07 | 2008-09-29 | Methods for inhibiting angiogenesis with inhibitors of proadrenomedullin N-terminal 20 peptide (PAMP) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42501802P | 2002-11-07 | 2002-11-07 | |
US60/425,018 | 2002-11-07 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10529116 A-371-Of-International | 2003-11-07 | ||
US12/240,656 Division US7862815B2 (en) | 2002-11-07 | 2008-09-29 | Methods for inhibiting angiogenesis with inhibitors of proadrenomedullin N-terminal 20 peptide (PAMP) |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2004043383A2 WO2004043383A2 (en) | 2004-05-27 |
WO2004043383A8 true WO2004043383A8 (en) | 2005-06-09 |
WO2004043383A3 WO2004043383A3 (en) | 2006-02-23 |
Family
ID=32312916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/035633 WO2004043383A2 (en) | 2002-11-07 | 2003-11-07 | A new target for angiogenesis and anti-angiogenesis therapy |
Country Status (6)
Country | Link |
---|---|
US (2) | US7462593B2 (en) |
EP (1) | EP1575511A4 (en) |
JP (1) | JP5068428B2 (en) |
AU (1) | AU2003295422B2 (en) |
CA (1) | CA2504953C (en) |
WO (1) | WO2004043383A2 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7393921B2 (en) * | 2000-12-04 | 2008-07-01 | Institute For Systems Biology | Prostate-specific polypeptide pamp and encoding nucleic acid molecules |
CA2501282C (en) | 2002-10-04 | 2012-12-04 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Vasoregulating compounds and methods of their use |
EP2339351A1 (en) * | 2003-09-08 | 2011-06-29 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide |
US8034773B2 (en) * | 2004-02-05 | 2011-10-11 | Arizona Biomedical Research Commission | Immunostimulatory compositions and uses thereof |
US8178649B2 (en) * | 2004-12-07 | 2012-05-15 | Arizona Biomedical Research Commission | Immunostimulatory compositions and uses thereof |
WO2006112390A1 (en) * | 2005-04-14 | 2006-10-26 | Japan As Represented By General Director Of Agency Of National Cardiovascular Center | Fat-derived progenitor cell and use thereof |
BRPI0613284A2 (en) * | 2005-06-17 | 2010-12-28 | Genentech Inc | acceleration methods of wound healing |
CA2615452C (en) | 2005-07-15 | 2015-03-31 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US20090062909A1 (en) | 2005-07-15 | 2009-03-05 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
CA2996768C (en) | 2006-04-26 | 2020-12-08 | Micell Technologies, Inc. | Coatings containing multiple drugs |
CA2667228C (en) | 2006-10-23 | 2015-07-14 | Micell Technologies, Inc. | Holder for electrically charging a substrate during coating |
US7838497B2 (en) * | 2006-12-13 | 2010-11-23 | Susavion Biosciences, Inc. | Pro-angiogenic peptides |
USRE46425E1 (en) | 2006-12-13 | 2017-06-06 | Susavion Biosciences, Inc. | Pro-angiogenic peptides and uses thereof |
US8460697B2 (en) * | 2006-12-13 | 2013-06-11 | Susavion Biosciences, Inc. | Pro-angiogenic peptides and uses thereof |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
CA2679712C (en) | 2007-01-08 | 2016-11-15 | Micell Technologies, Inc. | Stents having biodegradable layers |
AU2008256684B2 (en) | 2007-05-25 | 2012-06-14 | Micell Technologies, Inc. | Polymer films for medical device coating |
AU2008297542A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
EP2271294B1 (en) | 2008-04-17 | 2018-03-28 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
EP2324059A4 (en) * | 2008-07-01 | 2012-12-05 | Cephalon Australia Vic Pty Ltd | Anti-pamp therapeutic antibodies |
JP2011528275A (en) | 2008-07-17 | 2011-11-17 | ミセル テクノロジーズ,インク. | Drug delivery medical device |
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
US20100239635A1 (en) | 2009-03-23 | 2010-09-23 | Micell Technologies, Inc. | Drug delivery medical device |
CN102481195B (en) | 2009-04-01 | 2015-03-25 | 米歇尔技术公司 | Drug delivery medical device |
WO2010121187A2 (en) | 2009-04-17 | 2010-10-21 | Micell Techologies, Inc. | Stents having controlled elution |
EP2453834A4 (en) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | Drug delivery medical device |
US11369498B2 (en) | 2010-02-02 | 2022-06-28 | MT Acquisition Holdings LLC | Stent and stent delivery system with improved deliverability |
US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
WO2011133655A1 (en) | 2010-04-22 | 2011-10-27 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
CA2805631C (en) | 2010-07-16 | 2018-07-31 | Micell Technologies, Inc. | Drug delivery medical device |
WO2012166819A1 (en) | 2011-05-31 | 2012-12-06 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
CA2841360A1 (en) | 2011-07-15 | 2013-01-24 | Micell Technologies, Inc. | Drug delivery medical device |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
EP2905029B1 (en) | 2012-10-04 | 2018-11-21 | Shionogi&Co., Ltd. | Drug for inhibiting malignant tumor metastasis |
KR20150143476A (en) | 2013-03-12 | 2015-12-23 | 미셀 테크놀로지즈, 인코포레이티드 | Bioabsorbable biomedical implants |
KR102079613B1 (en) | 2013-05-15 | 2020-02-20 | 미셀 테크놀로지즈, 인코포레이티드 | Bioabsorbable biomedical implants |
JP6851819B2 (en) * | 2016-12-28 | 2021-03-31 | 源一郎 杣 | Capillary increase agent |
JPWO2022124341A1 (en) * | 2020-12-09 | 2022-06-16 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2774769B2 (en) * | 1993-04-26 | 1998-07-09 | 賢治 寒川 | Adrenomedullin |
US5831004A (en) * | 1994-10-27 | 1998-11-03 | Affymax Technologies N.V. | Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use |
WO1997007214A1 (en) | 1995-08-18 | 1997-02-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology |
US6440421B1 (en) * | 1996-04-18 | 2002-08-27 | Auchkland Uniservices Limited | Treatment of bone disorders with adrenomedullin or adrenomedullin agonists |
IT1296305B1 (en) * | 1997-07-17 | 1999-06-25 | Polifarma Spa | INHIBITORS OF METALLOPROTEINASE THEIR THERAPEUTIC USE AND PROCEDURE FOR THE PRODUCTION OF THE STARTING COMPOUND IN THEIR |
EP0926238A3 (en) | 1997-12-08 | 2000-11-22 | Smithkline Beecham Laboratoires Pharmaceutiques | Putative Adrenomedullin receptor polypeptide |
ES2184340T3 (en) * | 1997-12-23 | 2003-04-01 | Warner Lambert Co | COMBINATIONS OF INHIBITORS OF THE ANGIOTENSIN CONVERSION ENZYME AND INHIBITORS OF THE MATRIX METALOPROTEINASE ENZYME. |
US6169103B1 (en) * | 1998-03-03 | 2001-01-02 | Warner-Lambert | Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
AU4229499A (en) * | 1998-07-30 | 2000-02-21 | Warner-Lambert Company | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases |
US6117869A (en) * | 1998-08-04 | 2000-09-12 | Warner-Lambert Company | Compounds for and methods of inhibiting matrix metalloproteinases |
EP1623994A3 (en) * | 1999-05-17 | 2008-07-16 | ConjuChem Biotechnologies Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
EP1214600B1 (en) | 1999-09-10 | 2005-12-21 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Determination of adrenomedullin-binding proteins |
CA2501282C (en) | 2002-10-04 | 2012-12-04 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Vasoregulating compounds and methods of their use |
-
2003
- 2003-11-07 AU AU2003295422A patent/AU2003295422B2/en not_active Ceased
- 2003-11-07 WO PCT/US2003/035633 patent/WO2004043383A2/en active Application Filing
- 2003-11-07 CA CA2504953A patent/CA2504953C/en not_active Expired - Fee Related
- 2003-11-07 US US10/529,116 patent/US7462593B2/en not_active Expired - Fee Related
- 2003-11-07 EP EP03786608A patent/EP1575511A4/en not_active Withdrawn
- 2003-11-07 JP JP2004551922A patent/JP5068428B2/en not_active Expired - Fee Related
-
2008
- 2008-09-29 US US12/240,656 patent/US7862815B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP5068428B2 (en) | 2012-11-07 |
US20060160730A1 (en) | 2006-07-20 |
WO2004043383A3 (en) | 2006-02-23 |
US20090048170A1 (en) | 2009-02-19 |
EP1575511A4 (en) | 2006-06-28 |
US7862815B2 (en) | 2011-01-04 |
CA2504953C (en) | 2013-08-20 |
AU2003295422A1 (en) | 2004-06-03 |
AU2003295422B2 (en) | 2009-01-29 |
CA2504953A1 (en) | 2004-05-27 |
WO2004043383A2 (en) | 2004-05-27 |
EP1575511A2 (en) | 2005-09-21 |
JP2006516537A (en) | 2006-07-06 |
US7462593B2 (en) | 2008-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004043383A8 (en) | A new target for angiogenesis and anti-angiogenesis therapy | |
WO2003062265A3 (en) | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus | |
WO2004033659A3 (en) | Novel tumor suppressor gene and compositions and methods for making and using the same | |
MY134136A (en) | Novel compounds comprising jak3 kinase inhibitors | |
MXPA05012026A (en) | Azaindole compounds as kinase inhibitors. | |
TWI265927B (en) | Novel compounds as NS3-serine protease inhibitors of hepatitis C virus | |
NO20055863L (en) | W-carboxyaryl-substituted diphenylurea compounds as raf kinase inhibitors | |
WO2004014322A3 (en) | Immunomodulatory compositions, methods of making, and methods of use thereof | |
WO2004058769A3 (en) | Triazolopyridazines as protein kinases inhibitors | |
WO2002096361A3 (en) | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors | |
WO2002008198A3 (en) | Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus | |
WO2005056759A3 (en) | Methods of generating variant proteins with increased host string content and compositions thereof | |
WO2002014311A3 (en) | Urea compounds and methods of uses | |
WO2005079195A3 (en) | Pyrazolopyridines and analogs thereof | |
WO2005030130A3 (en) | Isoquinoline potassium channel inhibitors | |
NO20055612L (en) | Anti-inflammatory phosphonate compounds | |
WO2004093800A3 (en) | Thyronamine derivatives and analogs and methods of use thereof | |
WO2004007664A3 (en) | Nucleic acid vectors | |
WO2010000851A3 (en) | Methods for modulating angiogenesis via dystrophin dp71 | |
WO2003037863A3 (en) | Substituted indoles, method for production and use thereof for the inhibition of pain | |
AU2003211610A1 (en) | Pharmaceutical compositions for the treatment or prevention of osteoporosis | |
AU7525398A (en) | Inhibitors for urokinase receptor | |
WO2003077874A3 (en) | Substituted tetrahydroisoquinoline compounds, methods of making, and their use | |
WO2004098522A3 (en) | Gemini vitamin d3 compounds and methods of use thereof | |
WO2006052840A3 (en) | Bone tropic peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006160730 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10529116 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003295422 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2504953 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003786608 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004551922 Country of ref document: JP |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 22/2004 UNDER (71) THE NAME SHOULD READ "THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES" |
|
WWP | Wipo information: published in national office |
Ref document number: 2003786608 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10529116 Country of ref document: US |